Faeth Therapeutics, Inc.
FTHHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeFaeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company carries a $441.4M market cap, placing it firmly in the small-cap category. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Market Cap
$441.4M
Beta
-0.29
P/E (TTM)
—
P/E (Fwd)
-4.65
EPS (TTM)
$-60.86
EPS (Fwd)
$-3.67
ROE
-195.3%
ROA
-20.8%
Cash
$186.4M
Total Debt
$592,000
Free CF
$855,125
52W Change
68.8%
Annual Financials
Cash vs Debt
Where FTH stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, FTH finished 28.24% below its 150-day moving average ($27.09) and 21.55% below its 200-day moving average ($24.78). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FTH overbought or oversold?
At the October 20, 2026 close, FTH's RSI(14) was 24.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $186.4M in cash comfortably exceeding the $592K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $855K, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -195.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of -0.29 suggests FTH is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing FTH's risk profile alongside its fundamentals and technical indicators provides a more complete picture.